Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 2 Trials for Ponatinib (DB08901)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03147612Low-Intensity Chemotherapy and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment
NCT01424982Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaTreatment